Find
News Releases
= add release to Briefcase
| All Releases | |||
|---|---|---|---|
 |
Johnson & Johnson to Host Medical Devices & Diagnostics and Consumer Business Review May 29, 2008 |
5.7 KB |
|
|
NEW BRUNSWICK, N.J., May 29, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson will host an all-day review of its Medical Devices & Diagnostics businesses, as well as an update on its Consumer businesses, for the investment community beginning at 8:30 a.m. (Eastern Time) on Thursday, June 5, 2008, at the Hyatt Regency Hotel i... |
|||
|
Johnson & Johnson to Participate in Citi's Global Healthcare Conference May 15, 2008 |
5.4 KB |
|
|
NEW BRUNSWICK, N.J., May 15, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson will participate in Citi's Global Healthcare Conference on Thursday, May 22nd, at the Hilton New York in New York City. Sheri McCoy, Worldwide Chairman, Surgical Care, will represent the Company in a session scheduled at 10:30 a.m. (Eastern Time). ... |
|||
|
Biosense Webster Presents ''Complete Ablation Solutions'' to Electrophysiologists at Heart Rhythm 2008 May 13, 2008 |
8.1 KB |
|
|
DIAMOND BAR, Calif., May 13, 2008 (BUSINESS WIRE) -- Biosense Webster, Inc., the worldwide leader in the diagnosis and treatment of cardiac arrhythmias, will underscore the totality of its commitment to electrophysiologists and their catheter ablation practices at the Heart Rhythm Society's (HRS) 29th Annual Scientific Sessions by featuring its Com... |
|||
|
State-of-the-Art Cobalt Chromium Bare Metal Stent Now Available in Europe May 13, 2008 |
6.8 KB |
|
|
WARREN, N.J., May 13, 2008 (BUSINESS WIRE) -- Cordis Corporation today announced the availability of the PRESILLION(TM) Cobalt Chromium (CoCr) Coronary Stent in Europe. A bare metal stent, the PRESILLION(TM) stent provides flexibility that delivers the stent through the arteries, and conformability and scaffolding that adapts to the vessel when dep... |
|||
|
New Data From Phase 3 Study Suggests Tapentadol Immediate Release Effective For Acute Pain From Common Foot Surgery May 9, 2008 |
12.4 KB |
|
|
Novel Pain Medicine Studied in Patients Following Bunionectomy Tampa, FL - May 9, 2008 - Many foot-surgery patients experience intense pain for several days following removal of a bunion, one of the most common foot surgeries.1 The investigational pain medication tapentadol provided significant relief for patients who had t... |
|||
|
New Study Suggests Tapentadol IR For Acute Pain Is Associated With Improved Gastrointestinal Tolerability Compared To Oxycodone IR May 9, 2008 |
11.6 KB |
|
|
Tampa, FL - May 9, 2008 - Many strong acting pain medications have bothersome side effects. These can include nausea and vomiting with short-term use, and constipation with longer, chronic use.1 pg 17-18 Such symptoms can lead patients to discontinue treatment, adding additional complications to pain management for physicians. The novel investig... |
|||
|
Results Of Phase 3 Study Show Tapentadol Ir Relieves Acute Pain And Offers Favorable Gastrointestinal Tolerability Profile May 9, 2008 |
13.4 KB |
|
|
Tampa, FL - May 9, 2008 - Osteoarthritis is a painful and potentially debilitating condition that affects almost 50 million people in the United States.1 It is caused by deterioration of cartilage in bone joints. The novel investigational pain medication tapentadol, a centrally acting oral analgesic, provided significant relief for patients with... |
|||
|
Johnson & Johnson to Provide Webcast Presentation of Tapentadol Phase 3 Clinical Data Presented at American Pain Society's Annual Meeting May 7, 2008 |
6.0 KB |
|
|
NEW BRUNSWICK, N.J., May 7, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson will provide a pre-recorded webcast for financial analysts on Friday, May 9 at 4:00 p.m. (Eastern Time) to coincide with the American Pain Society's (APS) annual meeting in Tampa, Fla. Phase 3 clinical data presentations on investigational tapentado... |
|||
|
Johnson & Johnson to Participate in Deutsche Bank Health Care Conference Apr 29, 2008 |
5.4 KB |
|
|
NEW BRUNSWICK, N.J., April 29, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson will participate in the Deutsche Bank 33rd Annual Health Care Conference on Monday, May 5th at The InterContinental hotel in Boston. David Y. Norton, Company Group Chairman, Pharmaceuticals, will represent the Company in a session scheduled at 12... |
|||
|
Johnson & Johnson to Participate in Morgan Stanley Conference Apr 25, 2008 |
5.4 KB |
|
|
NEW BRUNSWICK, N.J., April 25, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson will participate in the Morgan Stanley Global Healthcare Unplugged Conference, on Thursday, May 1st at The Ritz-Carlton in Key Biscayne, Florida. Dominic Caruso, Vice President, Finance and Chief Financial Officer, will represent the Company in a... |
|||
|
Johnson & Johnson Announces Dividend Increase of 10.8% Apr 24, 2008 |
5.7 KB |
|
|
NEW BRUNSWICK, N.J., April 24, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson today announced that its Board of Directors has declared a 10.8% increase in the quarterly dividend rate, from $.415 per share to $.46 per share. The increase was announced this morning at the Annual Shareholders Meeting in New Brunswick, NJ. ... |
|||
|
Johnson & Johnson to Webcast Annual Meeting of Shareholders Apr 22, 2008 |
5.7 KB |
|
|
NEW BRUNSWICK, N.J., April 22, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson will webcast its Annual Meeting of shareholders at 10 a.m. (Eastern Time) on Thursday, April 24. Investors and other interested parties may access the meeting by visiting the Company's website at www.jnj.com, and clicking on the webcast icon. A r... |
|||
|
Johnson & Johnson Reports 2008 First-Quarter Results: Apr 15, 2008 |
19.8 KB |
|
|
NEW BRUNSWICK, N.J., April 15, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson today announced record sales of $16.2 billion for the first quarter of 2008, an increase of 7.7% as compared to the first quarter of 2007. Operational growth was 2.6% and currency contributed 5.1%. Domestic sales were up 2.8%, while international... |
|||
|
Ortho Biotech Oncology Research & Development Unites
Johnson & Johnson Biopharmaceutical Oncology R&D Assets
Apr 11, 2008 |
12.7 KB |
|
|
San Diego, Calif., April 11 2008 - Ortho Biotech Oncology Research & Development (ORD), a unit of Johnson & Johnson Pharmaceutical Research & Development, L.L.C., will announce results from studies of three innovative compounds-Hdm2, c-Met, and HDAC inhibitors-here at the American Association for Cancer Research (AACR) 2008 Annual Me... |
|||
|
NEJM Study Demonstrates Carotid Stenting with Embolic Protection is Comparable to Surgery Apr 9, 2008 |
9.0 KB |
|
|
WARREN, N.J., Apr 09, 2008 (BUSINESS WIRE) -- According to a study published in The New England Journal of Medicine this week, three-year data from the Stenting and Angioplasty with Protection in Patients at High Risk for Endarterectomy (SAPPHIRE) study in patients with severe blocked carotid arteries, the main blood vessels in the neck leading to ... |
|||
|
Johnson & Johnson to Host Analyst Conference Call on First-Quarter Results Apr 8, 2008 |
5.5 KB |
|
|
NEW BRUNSWICK, N.J., April 8, 2008, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson will host a conference call for financial analysts at 8:30 a.m. (Eastern Time) on Tuesday, April 15, 2008, to review first-quarter results. Dominic Caruso, Vice President, Finance and Chief Financial Officer, and Louise Mehrotra, Vice Presid... |
|||
|
Data From Ortho Biotech-Sponsored Studies To Be Presented At National Kidney Foundation 2008 Spring Clinical Meetings Apr 4, 2008 |
14.0 KB |
|
|
DALLAS (April 4, 2008) - Data from five studies sponsored by Ortho Biotech Products, L.P. will be presented at the National Kidney Foundation (NKF) 2008 Spring Clinical Meetings from April 2 - 6, 2008; three utilization studies involve PROCRIT® (Epoetin alfa). The data include studies that compare drug utilization patterns and costs of P... |
|||
| First New NNRTI in Nearly a Decade to Benefit Canadians with HIV/AIDS Apr 1, 2008 |
205.1 KB |
|
|
|
Three Year Follow-up Data Suggest Better Outcomes Were Maintained with the CYPHER(R) Sirolimus-Eluting Coronary Stent Compared to Brachytherapy in Patients with In-Stent Reblockage Mar 30, 2008 |
8.6 KB |
|
|
CHICAGO, Mar 30, 2008 (BUSINESS WIRE) -- Long-term, follow-up data presented today suggest that patients who received the CYPHER(R) Sirolimus-eluting Coronary Stent for blockage of a bare metal stent were significantly less likely to need another procedure (target lesion revascularization or TLR) at three years compared to patients who received bra... |
|||
|
Ortho-Clinical Diagnostics Receives FDA Approval for New HIV Test Mar 28, 2008 |
8.7 KB |
|
|
Raritan, NJ (March 28, 2008) – Ortho-Clinical Diagnostics announced U.S. Food and Drug Administration approval of a new diagnostic assay for the detection of antibodies to Human Immunodeficiency Virus types 1 and/or 2 (anti HIV-1 and anti HIV-2). The new VITROS® Anti-HIV 1+2 assay1 can be run in a fully automated, random access format on the V... |
|||
= add release to Briefcase
